Email Us
View Reports

Renal Biomarkers market

Renal Biomarkers market Analysis - By Type (Functional Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-Regulated Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 & INTERLEUKIN-18), By Diagnostic Technique (Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA) & Liquid Chromatography Mass Spectrometry (LS-MS), By End-user (Hospitals, Diagnostic Laboratory & Others), By Region (North America (United States & Canada), Europe (United Kingdom, Italy, Germany, Spain, France & Rest of Europe), Asia Pacific (India, China, Japan, South Korea, Australia, New Zealand, Rest of APAC), Latin America (Brazil, Mexico, Argentina & Rest of Latin America), Middle East & Africa) - Global Industry Size, Share, Growth, Demand, Strategy & Forecast Report | 2019 - 2025

  • ID : 50168439  |  
  • Published : Oct-2019  |  
  • Region : Global  |  
  • Pages : 150   |  
  • Publisher : Mordor Intelligence

Renal Biomarkers Market Size, Share & Forecast (2019 - 2025)

Global Renal Biomarkers Market is expected to be valued at USD 1023.04 million in 2019 and to be valued at USD 1552.60 million in 2025, witnessing a CAGR of 7.20% during the forecast period of 2019 - 2025.

Growth Factors

  • The key factors propelling the growth of this market are the rising prevalence of various kidney-related diseases, the high prevalence of diabetes and high blood pressure which are the leading causes of renal diseases, and rapid technological advances in the field of genetics.

  • Advances in the field of genetic technology during the last decade have enlightened our knowledge regarding genetic regulatory pathways related to renal biomarkers.

  • Due to rapid advances in genomic technologies, genetics analyses have become essential in clinical practice and research.

  • Moreover, with the development of computer technology, renal biomarkers testing has become widely accessible and feasible to perform, even in small size laboratories.


Recent advances in genetics have created opportunities to study kidney disease in a variety of platforms, applied to human populations. Renal biomarkers can also be integrated into genetic level technological advancements for the detection, diagnosis, and treatment of kidney diseases. These rapid advances in genetics led to the development of more advanced renal biomarkers for treating kidney diseases, which ultimately drives the market.

Key Market Trends:

  • Functional Biomarker is Expected to hold its Highest Market Share in the Biomarker Type Segment

  • In the biomarker type segment of the Renal Biomarkers market, the functional biomarker is believed to have the largest market size and is expected to witness a CAGR of 6.94% in the forecast period 2019 - 2025.

  • Chronic kidney disease (CKD) has become a public-health problem. According to the National Institute of Diabetes, Digestives and Kidney Diseases, the overall prevalence of CKD in the general population is approximately 14%, and around 6,61,000 Americans have kidney failure. Currently, the diagnosis of CKD is made usually on the levels of serum creatinine (SCr). The serum creatinine, a functional biomarker dominates the market of renal biomarkers owing to the high prevalence rate of CKD and high presence and knowledge of serum creatinine biomarkers.

This Research Report includes the Segmentation of Global Renal Biomarkers Market:

Global Renal Biomarkers Market - By Type

  • Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
  • Up-Regulated Protein
  • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  • Kidney Injury Molecule-1

Global Renal Biomarkers Market - By Diagnostic Technique

  • Enzyme-Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay (PETIA)
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay (CLIA)
  • Liquid Chromatography-Mass Spectrometry (LS-MS)

Global Renal Biomarkers Market - By End User

  • Hospitals
  • Diagnostic Laboratory
  • Others

Global Renal Biomarkers Market - By Region

  • North America

    • US
    • Canada
    • Mexico

  • Europe

    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe

  • Asia Pacific

    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific

  • Middle East and Africa

    • GCC
    • South Africa
    • Rest of the Middle East and Africa

  • South America

    • Brazil
    • Argentina
    • Rest of South America

Regionally, North America currently dominates the market for Renal Biomarkers and is expected to continue its stronghold for a few more years. In the North America region, the United States holds the largest market share. Over the past decade, there has been a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures. Molecular biomarkers are expected to be identified and validated in drug development and be used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.

Major Players in the Renal Biomarkers Market Listed as per the Research Report are:

  1. Thermo Fischer Scientific Inc

  2. Abbott Laboratories

  3. Siemens Healthcare GmbH

  4. F. Hoffmann-La Roche AG

  5. bioMerieux SA


1. Study Deliverables

2. Study Assumptions

3. Scope of the Study




1. Market Overview

2. Market Drivers

1. Rising Prevalence Of Various Kidney-Related Diseases

2. The High Prevalence Of Diabetes And High Blood Pressure, The Leading Cause Of Renal Diseases

3. Rapid Technological Advances In The Field Of Genetics

3. Market Restraints

1. Issues Related To Regulatory And Reimbursement Systems

4. Porter's Five Force Analysis

1. Threat of New Entrants

2. Bargaining Power of Buyers/Consumers

3. Bargaining Power of Suppliers

4. Threat of Substitute Products

5. Intensity of Competitive Rivalry


1. Biomarker Type

1. Functional Biomarker

1. Serum Creatinine

2. Serum Cystatin C

3. Urine Albumin

2. Up-Regulated Protein

1. Neutrophil Gelatinase-Associated Lipocalin (NGAL)

2. Kidney Injury Molecule-1


2. Diagnostic Technique

1. Enzyme-Linked Immunosorbent Assay

2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

3. Colorimetric Assay

4. Chemiluminescent Enzyme Immunoassay (CLIA)

5. Liquid Chromatography Mass Spectrometry (LS-MS)

3. End User

1. Hospitals

2. Diagnostic Laboratory

3. Others

4. Geography

1. North America

1. US

2. Canada

3. Mexico

2. Europe

1. Germany

2. UK

3. France

4. Italy

5. Spain

6. Rest of Europe

3. Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Rest of Asia-Pacific

4. Middle East and Africa

1. GCC

2. South Africa

3. Rest of Middle East and Africa

5. South America

1. Brazil

2. Argentina

3. Rest of South America


1. Company Profiles

1. Beckman Coulter Inc. (Danaher Corporation)

2. Thermo Fisher Scientific Inc

3. Abbott Molecular Inc (Abbott Laboratories Ltd)

4. Bioporto A/S

5. Astute Medical Inc

6. Randox Laborotories Ltd

7. Siemens Healthcare

8. Cobo Scientific Biomedical Research

9. F. Hoffmann-La Roche Ag

10. Biomerieux

*List Not Exhaustive


Purchase this Market Research Report


Call us on : +1 888 709 8757

Drop us an email at :